Cisplatin-based chemotherapy does not eliminate the risk of a second testicular cancer.
Of 781 patients with germ cell cancer, 14 developed a second (subsequent) testicular cancer during follow-up. The incidence was not related to the treatment of the first germ cell cancer. In particular, adequate cisplatin-based chemotherapy did not reduce the risk of developing a second tumour. Screening programmes in patients with previous germ cell tumours should include all patients, irrespective of prior treatment.
Fosså
S D
SD
Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
Aass
N
N
D000328:Adult; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000532:radiotherapy; D012307:Risk Factors; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy
D002945:Cisplatin